Wells Fargo’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,211
| Closed | -$47.4K | – | 7774 |
|
|
2024
Q1 | $47.4K | Buy |
3,211
+419
| +15% | +$5.89K | ﹤0.01% | 5273 |
|
|
2023
Q4 | $37.4K | Buy |
2,792
+619
| +28% | +$7.82K | ﹤0.01% | 5383 |
|
|
2023
Q3 | $26.8K | Sell |
2,173
-2,273
| -51% | -$27.5K | ﹤0.01% | 5476 |
|
|
2023
Q2 | $54.7K | Buy |
4,446
+4,276
| +2,515% | +$53.5K | ﹤0.01% | 5391 |
|
|
2023
Q1 | $2.09K | Buy |
170
+2
| +1% | +$24 | ﹤0.01% | 6216 |
|
|
2022
Q4 | $1.93K | Sell |
168
-71
| -30% | -$585 | ﹤0.01% | 6019 |
|
|
2022
Q3 | $1K | Buy |
239
+117
| +96% | +$540 | ﹤0.01% | 6566 |
|
|
2022
Q2 | $0 | Buy |
122
+6
| +5% | +$34 | ﹤0.01% | 8049 |
|
|
2022
Q1 | $0 | Hold |
116
| – | – | ﹤0.01% | 8379 |
|
|
2021
Q4 | $0 | Hold |
116
| – | – | ﹤0.01% | 8332 |
|
|
2021
Q3 | $0 | Sell |
116
-20
| -15% | -$104 | ﹤0.01% | 7970 |
|
|
2021
Q2 | $1K | Sell |
136
-1
| -0.7% | -$7 | ﹤0.01% | 6827 |
|
|
2021
Q1 | $1K | Hold |
137
| – | – | ﹤0.01% | 6834 |
|
|
2020
Q4 | $1K | Buy |
137
+5
| +4% | +$25 | ﹤0.01% | 6421 |
|
|
2020
Q3 | $0 | Buy |
132
+4
| +3% | +$15 | ﹤0.01% | 7353 |
|
|
2020
Q2 | $0 | Hold |
128
| – | – | ﹤0.01% | 7265 |
|
|
2020
Q1 | $0 | Buy |
128
+78
| +156% | +$228 | ﹤0.01% | 7312 |
|
|
2019
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 7059 |
|
|
2019
Q3 | $0 | Sell |
50
-14
| -22% | -$70 | ﹤0.01% | 7022 |
|
|
2019
Q2 | $0 | Hold |
64
| – | – | ﹤0.01% | 6860 |
|
|
2019
Q1 | $0 | Buy |
+64
| New | +$294 | ﹤0.01% | 6781 |
|
|
2018
Q2 | – | Sell |
-23,942
| Closed | -$151K | – | 6844 |
|
|
2018
Q1 | $151K | Buy |
23,942
+699
| +3% | +$5.79K | ﹤0.01% | 5123 |
|
|
2017
Q4 | $187K | Buy |
23,243
+15,991
| +221% | +$149K | ﹤0.01% | 4991 |
|
|
2017
Q3 | $83K | Sell |
7,252
-3,421
| -32% | -$36K | ﹤0.01% | 5305 |
|
|
2017
Q2 | $104K | Sell |
10,673
-8
| -0.1% | -$163 | ﹤0.01% | 5157 |
|
|
2017
Q1 | $259K | Sell |
10,681
-128
| -1% | -$3.2K | ﹤0.01% | 4659 |
|
|
2016
Q4 | $347K | Buy |
10,809
+4,048
| +60% | +$173K | ﹤0.01% | 4451 |
|
|
2016
Q3 | $338K | Sell |
6,761
-765
| -10% | -$31.8K | ﹤0.01% | 4174 |
|
|
2016
Q2 | $320K | Sell |
7,526
-1,351
| -15% | -$73.6K | ﹤0.01% | 4149 |
|
|
2016
Q1 | $585K | Buy |
8,877
+796
| +10% | +$41.6K | ﹤0.01% | 3776 |
|
|
2015
Q4 | $502K | Buy |
8,081
+2,854
| +55% | +$201K | ﹤0.01% | 3922 |
|
|
2015
Q3 | $349K | Sell |
5,227
-99
| -2% | -$8.08K | ﹤0.01% | 4172 |
|
|
2015
Q2 | $518K | Buy |
5,326
+4,309
| +424% | +$410K | ﹤0.01% | 4066 |
|
|
2015
Q1 | $94K | Sell |
1,017
-52
| -5% | -$4.43K | ﹤0.01% | 4764 |
|
|
2014
Q4 | $95K | Sell |
1,069
-1,196
| -53% | -$87.1K | ﹤0.01% | 4756 |
|
|
2014
Q3 | $157K | Sell |
2,265
-151
| -6% | -$8.07K | ﹤0.01% | 4456 |
|
|
2014
Q2 | $139K | Sell |
2,416
-1,088
| -31% | -$55.2K | ﹤0.01% | 4545 |
|
|
2014
Q1 | $139K | Buy |
+3,504
| New | +$150K | ﹤0.01% | 4505 |
|
Other funds holding MACK
RA
JC
Wells Fargo's MACK Position: Q2 2024 in Review
Wells Fargo sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 3,211 shares — an estimated $47.4K sold.
Wells Fargo first reported a position in MACK in Q1 2014 and held it in 38 quarters. The position peaked at $585K in Q1 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Wells Fargo reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 3,211 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $47.4K.
- Wells Fargo first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2014 and held it in 38 quarters.
- Wells Fargo's Merrimack Pharmaceuticals, Inc. position peaked at $585K in Q1 2016.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.